Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Question

Below is copy taken from TPL's press release regarding the last terminated re-exam. Note that the USPTO posted the information on 9/11, however, the press release is dated 9/16.

Please note that it references an end to the re-exam initiated by J3. Why wouldn't the J3 have withdrawn their request for re-exam at the time of the settlement and NDA? Why pursue re-exam if there was nothing left on the table? Hmmmmm

CUPERTINO, Calif. – September 16, 2009 – Alliacense announced today that the USPTO has affirmed the validity of US’336, the most widely recognized patent in the MMP Portfolio™.

The TPL Group has extended its remarkable string of successes against multiple validity attacks on the MMP Portfolio perpetrated by numerous electronics industry giants from around the world. These victories significantly strengthen the MMP Portfolio patents – and accordingly, magnify the risk for those companies without a license to the technology. Recent key victories include:

August - September 2009. The USPTO indicates it will issue a Reexamination Certificate for the US’336 “Dual Asynchronous Clock” patent, ending eexaminations filed by NEC, Toshiba, and the Public Patent Foundation; and resoundingly rejects another attempted attack by litigant HTC.

Share
New Message
Please login to post a reply